To evaluate the efficacy of an eosinophil-guided approach for determining the duration of systemic corticosteroid therapy in hospitalized asthma patients.
Key Findings:
The eosinophil-guided approach met noninferiority criteria and reduced cumulative steroid exposure in noneosinophilic exacerbations.
Treatment failure occurred in 11% of eosinophil-guided patients and 7% of usual care patients, with no significant differences in overall outcomes.
No deaths or severe complications requiring mechanical ventilation were reported.
Interpretation:
Using baseline blood eosinophil counts to guide corticosteroid duration is effective and may reduce unnecessary steroid exposure without compromising patient safety.
Limitations:
Open-label design may introduce bias in treatment failure assessments.
The broad noninferiority margin of 20% could affect the robustness of findings.
Limited generalizability due to the study being conducted at two centers in Singapore.
Conclusion:
Eosinophil-guided corticosteroid duration is a viable alternative to standard care, particularly for noneosinophilic asthma exacerbations, warranting further research in larger, diverse populations.
